Local angiotensin II aggravates cardiac remodeling in hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 5, 2010, Pages

  Xu, Jiang ^a   Carretero, Oscar A ^a   Liao, Tang Dong ^a   Peng, Hongmei ^a   Shesely, Edward G ^a   Xu, Junxiao ^a   Liu, Thomas S ^a   Yang, James J ^a   Reudelhuber, Timothy L ^b   Yang, Xiao Ping ^a  

^a HENRY FORD HOSPITAL   (United States)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Cardiac hypertrophy; Fibrosis; Inflammation; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; COLLAGEN; DEOXYCORTICOSTERONE ACETATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC REMODELING; CELL DEATH; CELL INFILTRATION; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE VOLUME;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; COLLAGEN; DESOXYCORTICOSTERONE; DINOPROST; DISEASE MODELS, ANIMAL; HEART RATE; HYPERTENSION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; VALINE;

EID: 78249242127     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00538.2010     Document Type: Article

References (45)

1. Barrett G, Morgan T, Smith M, Aldred P. Effect of mineralocorticoids and salt loading on renin release, renal renin content and renal renin mRNA in mice. Clin Exp Pharmacol Physiol 16: 631-639, 1989.
2. Basile J, Toth PP. Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J 102: S1-S12, 2009.
3. Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 35: 759-768, 2003.
4. Ferder L, Inserra F, Martinez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 8: 191-198, 2006.
5. Fintel DJ. The role of RAS modification for primary and secondary stroke prevention. Postgrad Med 121: 115-122, 2009.
6. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101: 660-667, 2000.
7. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532-1541, 1997.
8. Hingtgen SD, Tian X, Yang J, Dunlay SM, Peek AS, Wu Y, Sharma RV, Engelhardt JF, Davisson RL. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics 26: 180-191, 2006.
9. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20: 1546-1548, 2006.
10. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007.
11. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin-II-induced hypertension. Hypertension 52: 256-263, 2008.
12. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997.
13. Mateo T, bu Nabah YN, Abu TM, Mata M, Cerda-Nicolas M, Proudfoot AE, Stahl RA, Issekutz AC, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 176: 5577-5586, 2006.
14. Matsui T, Nagoshi T, Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2: 220-223, 2003.
15. Matsui T, Tao J, del MF, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104: 330-335, 2001.
16. Matsusaka T, Katori H, Inagami T, Fogo A, Ichikawa I. Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. J Clin Invest 103: 1451-1458, 1999.
17. Neri Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88: 961-968, 2001.
18. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, Fujiwara T, Fujiwara H. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with In situ nick endlabeling. Circulation 98: 1422-1430, 1998.
19. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 97: 931-936, 2000.
20. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
21. Peng H, Carretero OA, Alfie ME, Masura JA, Rhaleb NE. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. Hypertension 37: 974-980, 2001.
22. Peng H, Carretero OA, Liao TD, Peterson EL, Rhaleb NE. Role of Ac-SDKP in the antifibrotic effect of angiotensin-converting enzyme inhibitors in hypertension-induced target organ damage. Hypertension 49: 1-9, 2007.
23. Polizio AH, Balestrasse KB, Yannarelli GG, Noriega GO, Gorzalczany S, Taira C, Tomaro ML. Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension. Hypertens Res 31: 325-334, 2008.
24. Ravandi A, Teo KK. Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Rev Cardiovasc Ther 7: 667-674, 2009.
25. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension 49: 1196-1201, 2007.
26. Sadoshima J, Izumo S. Molecular characterization of angiotensin IIinduced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423, 1993.
27. 2α. Hypertension 33: 424-428, 1999.
28. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, Redfield MM. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension 51: 289-295, 2008.
29. Skultetyova D, Filipova S, Riecansky I, Skultety J. The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Pat Cardiovasc Drug Discov 2: 23-27, 2007.
30. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 81: 482-490, 2009.
31. Sun Y, Carretero OA, Xu J, Rhaleb NE, Wang F, Lin C, Yang JJ, Pagano PJ, Yang XP. Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate-salt hypertension. Hypertension 46: 1355-1361, 2005.
32. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900, 2003.
33. Sweat F, Puchtler H, Rosenthal SI. Sirius Red F3BA as a stain for connective tissue. Arch Pathol 78: 69-72, 1964.
34. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49: 241-248, 2007.
35. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res 37: 1263-1273, 2004.
36. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 274: 22699-22704, 1999. (Pubitemid 29379317)
37. vanKats JP, Methot D, Paradis P, Silversides DW, Reudelhuber TL. Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart. J Biol Chem 276: 44012-44017, 2001.
38. Werner CM, Bohm M. The therapeutic role of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis 2: 167-177, 2008. (Pubitemid 351863375)
39. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma L, Qazi M, Link D, Karuparthi PR, Stump C, Ferrario C, Sowers JR. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 293: E355-E363, 2007. (Pubitemid 47105951)
40. Xu J, Carretero OA, Cavasin MA, Lin C, Shesely EG, Yang JJ, Reudelhuber TL, Yang XP. Role of cardiac overexpression of angiotensin ii in the regulation of cardiac function and remodeling post-myocardial infarction. Am J Physiol Heart Circ Physiol 293: H1900-H1907, 2007. (Pubitemid 47367241)
41. 1 antagonists in mice. Hypertension 40: 244-250, 2002.
42. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10: 83-89, 2004.
43. 1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45: 747-753, 2005.
44. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol Heart Circ Physiol 277: H1967-H1974, 1999.
45. Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah AM, Cave AC. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 113: 1235-1243, 2006.